Search
Citius Oncology Inc
CTORAdd to Watchlist
0.596USD
+0.016+2.76%
Close 10-26 16:00（ET）
55.42MMarket Cap
LossP/E TTM
After-hours 18:01 (ET)0.558USD-0.033-5.58%
After-hours 18:01 (ET)Citius Oncology Inc (CTOR) Stock Price Target & Forecast
Analyst Rating
Based on 1 analysts giving stock ratings to Citius Oncology Inc in the past month.
Buy
0 Strong Buy
1 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
4.000USD+420.90%
CTOR Analyst Recommendation Trends
In the current month, CTOR has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CTOR average Analyst price target in the last month is 4.000.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
CTOR Analyst Rating for Peer Comparison
Updated: Oct 20, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
10
14
3
0
0
27
Beigene Ltd
ONC
8
19
0
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Revolution Medicines Inc
RVMD
10
14
1
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Biontech SE
BNTX
4
12
8
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Cytokinetics Inc
CYTK
5
16
2
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Financial Forecasting
Based on analysts' estimates, CTOR EPS is projected to reach -0.210 in FY2026Q4, following reported EPS of -0.083 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
0.06
-0.01
-0.08
-0.21
--
Actual
-0.06
-0.27
-0.08
--
--
Surprise
-205.45%
-2560.20%
-3.39%
--
--
FAQs
What is Citius Oncology Inc's expected revenue for the next quarter?
Citius Oncology Inc's expected revenue is 5.77M.
What is Citius Oncology Inc's price target?
Analysts forecast that Citius Oncology Inc's price target is USD 4.00, with the highest forecast at USD 4.00 and the lowest forecast at USD 4.00.
How have Citius Oncology IncCTOR's recent earnings per share performed?
The market expectation was USD -0.08, while Citius Oncology IncCTOR's earnings per share (EPS) for the previous quarter was USD -0.27. EPS for the next quarter is expected at USD -0.21.
What is the analyst rating for Citius Oncology Inc?
Based on the ratings of Citius Oncology Inc's stock from 1 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.